Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors

Lu Zhou, Ying Liu, Weilin Zhang, Ping Wei, Changkang Huang, Jianfeng Pei, Yaxia Yuan, Luhua Lai

Resultado de la investigación: Articlerevisión exhaustiva

104 Citas (Scopus)


A series of isatin derivatives were synthesized and tested against SARS CoV 3C-like protease. Substitutions at the N-1 and C-5 positions were examined to elucidate the differences in substrate binding sites of the rhinovirus 3C protease and SARS CoV 3C-like protease. Compound Sf shows significant inhibition with an IC50 of 0.37 μM. Further study showed that, unlike the irreversible covalent binding of isatin derivatives to human rhinovirus 3C protease, the compounds tested in this study are all noncovalent reversible inhibitors.

Idioma originalEnglish (US)
Páginas (desde-hasta)3440-3443
Número de páginas4
PublicaciónJournal of Medicinal Chemistry
EstadoPublished - jun 15 2006
Publicado de forma externa

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Profundice en los temas de investigación de 'Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors'. En conjunto forman una huella única.

Citar esto